When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering

Journal of the American College of Cardiology

Volumn 68, Issue 7, 2016, Pages 754-762

  Messerli, Franz H ^a,b,c   Rimoldi, Stefano F ^a   Bangalore, Sripal ^d   Bavishi, Chirag ^e   Laurent, Stephane ^f  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Mount Sinai St Luke's and Mount Sinai West Hospitals   (United States)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

beta blockers; blood pressure; coronary artery disease; heart failure; hypertension; ivabradine

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; IVABRADINE; PRAVASTATIN; PROPRANOLOL; TRANDOLAPRILAT; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ARTERIAL STIFFNESS; ATHLETE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART STROKE VOLUME; HEART WORK; HOSPITAL READMISSION; HUMAN; HYPERTENSION; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; REVIEW; SURVIVAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG EFFECTS; HEART RATE; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEART RATE; HUMANS; HYPERTENSION; SYSTOLE;

EID: 84994759909     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.610     Document Type: Review

References (68)

1. 1 Kannel, W.B., Kannel, C., Paffenbarger, R.S. Jr., et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113 (1987), 1489–1494.
2. 2 Gillman, M.W., Kannel, W.B., Belanger, A., et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 125 (1993), 1148–1154.
3. 3 Gillum, R.F., Makuc, D.M., Feldman, J.J., Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 121 (1991), 172–177.
4. 4 Benetos, A., Rudnichi, A., Thomas, F., et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 33 (1999), 44–52.
5. 5 Jouven, X., Empana, J.P., Schwartz, P.J., et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 352 (2005), 1951–1958.
6. 6 Palatini, P., Thijs, L., Staessen, J.A., et al., Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 162 (2002), 2313–2321.
7. 7 Thomas, F., Rudnichi, A., Bacri, A.M., et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 37 (2001), 1256–1261.
8. 8 Dyer, A.R., Persky, V., Stamler, J., et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112 (1980), 736–749.
9. 9 McAlister, F.A., Wiebe, N., Ezekowitz, J.A., et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 (2009), 784–794.
10. 10 Palatini, P., Benetos, A., Grassi, G., et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 24 (2006), 603–610.
11. 11 Fox, K., Borer, J.S., Camm, A.J., et al., Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50 (2007), 823–830.
12. 12 Cook, S., Togni, M., Schaub, M.C., et al. High heart rate: a cardiovascular risk factor?. Eur Heart J 27 (2006), 2387–2393.
13. 13 Narkiewicz, K., Somers, V.K., Interactive effect of heart rate and muscle sympathetic nerve activity on blood pressure. Circulation 100 (1999), 2514–2518.
14. 14 Mokrane, A., Nadeau, R., Dynamics of heart rate response to sympathetic nerve stimulation. Am J Physiol 275 (1998), H995–H1001.
15. 15 Grassi, G., Vailati, S., Bertinieri, G., et al. Heart rate as marker of sympathetic activity. J Hypertens 16 (1998), 1635–1639.
16. 16 La Rovere, M.T., Pinna, G.D., Hohnloser, S.H., et al., Autonomic Tone and Reflexes After Myocardial Infarction (ATRAMI) Investigators. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 103 (2001), 2072–2077.
17. 17 Flaa, A., Mundal, H.H., Eide, I., et al. Sympathetic activity and cardiovascular risk factors in young men in the low, normal, and high blood pressure ranges. Hypertension 47 (2006), 396–402.
18. 18 Rostrup, M., Westheim, A., Kjeldsen, S.E., et al. Cardiovascular reactivity, coronary risk factors, and sympathetic activity in young men. Hypertension 22 (1993), 891–899.
19. 19 Grassi, G., Seravalle, G., Cattaneo, B.M., et al. Sympathetic activation in obese normotensive subjects. Hypertension 25 (1995), 560–563.
20. 20 Carnethon, M.R., Golden, S.H., Folsom, A.R., et al. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987-1998. Circulation 107 (2003), 2190–2195.
21. 21 Tverdal, A., Hjellvik, V., Selmer, R., Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J 29 (2008), 2772–2781.
22. 22 Diaz, A., Bourassa, M.G., Guertin, M.C., et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26 (2005), 967–974.
23. 23 Levine, H.J., Rest heart rate and life expectancy. J Am Coll Cardiol 30 (1997), 1104–1106.
24. 24 Azbel, MYa, Universal biological scaling and mortality. Proc Natl Acad Sci U S A 91 (1994), 12453–12457.
25. 25 Perski, A., Hamsten, A., Lindvall, K., et al. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 116 (1988), 1369–1373.
26. 26 Perski, A., Olsson, G., Landou, C., et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 123 (1992), 609–616.
27. 27 Heidland, U.E., Strauer, B.E., Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104 (2001), 1477–1482.
28. 28 Goldberg, R.J., Larson, M., Levy, D., Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med 156 (1996), 505–509.
29. 29 Benetos, A., Thomas, F., Bean, K., et al. Resting heart rate in older people: a predictor of survival to age 85. J Am Geriatr Soc 51 (2003), 284–285.
30. 30 Bassiouny, H.S., Zarins, C.K., Kadowaki, M.H., et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 19 (1994), 426–434.
31. 31 Kaplan, J.R., Manuck, S.B., Adams, M.R., et al. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 76 (1987), 1364–1372.
32. 32 Beere, P.A., Glagov, S., Zarins, C.K., Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226 (1984), 180–182.
33. 33 Beere, P.A., Glagov, S., Zarins, C.K., Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey. Localization, compensatory enlargement, and the sparing effect of lowered heart rate. Arterioscler Thromb 12 (1992), 1245–1253.
34. 34 Kjekshus, J.K., Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57 (1986), 43F–49F.
35. 35 Fox, K., Ford, I., Steg, P.G., et al., BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 807–816.
36. 36 Fox, K., Ford, I., Steg, P.G., et al., SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371 (2014), 1091–1099.
37. 37 Belz, G.G., Elastic properties and Windkessel function of the human aorta. Cardiovasc Drugs Ther 9 (1995), 73–83.
38. 38 Mangoni, A.A., Mircoli, L., Giannattasio, C., et al. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 14 (1996), 897–901.
39. 39 Nichols, W.V., O'Rourke, M.F., McDonald's Blood Flow in Arteries: Theoretical, Experimental, and Clinical Principles. 3rd edition, 1990, Edward Arnold, London, United Kingdom.
40. 40 Wilkinson, I.B., MacCallum, H., Flint, L., et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 525 (2000), 263–270.
41. 41 Wilkinson, I.B., Mohammad, N.H., Tyrrell, S., et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 15 (2002), 24–30.
42. 42 Whelton, S.P., Blankstein, R., Al-Mallah, M.H., et al. Association of resting heart rate with carotid and aortic arterial stiffness: multi-ethnic study of atherosclerosis. Hypertension 62 (2013), 477–484.
43. 43 Aronow, W.S., Fleg, J.L., Pepine, C.J., et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 57 (2011), 2037–2114.
44. 44 Nichols, W.W., Denardo, S.J., Davidson, J.B., et al. Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: an ancillary study from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 170 (2015), 1243–1254.
45. 45 Hoffman, J.I., A critical view of coronary reserve. Circulation 75 (1987), I6–I11.
46. 46 Ohtsuka, S., Kakihana, M., Watanabe, H., et al. Chronically decreased aortic distensibility causes deterioration of coronary perfusion during increased left ventricular contraction. J Am Coll Cardiol 24 (1994), 1406–1414.
47. 47 Leung, M.C., Meredith, I.T., Cameron, J.D., Aortic stiffness affects the coronary blood flow response to percutaneous coronary intervention. Am J Physiol Heart Circ Physiol 290 (2006), H624–H630.
48. 48 Bangalore, S., Messerli, F.H., Ou, F.S., et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 31 (2010), 552–560.
49. 49 Bangalore, S., Qin, J., Murphy, S., et al. Relationship of heart rate and cardiovascular events in patients after acute coronary syndromes: an analysis from the PROVE-IT TIMI 22 trial (abstr). J Am Coll Cardiol, 55, 2010, A98.E924.
50. 50 Kolloch, R., Legler, U.F., Champion, A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29 (2008), 1327–1334.
51. 51 Bangalore, S., Messerli, F.H., Wun, C.C., et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 31 (2010), 2897–2908.
52. 52 Bangalore, S., Sawhney, S., Messerli, F.H., Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52 (2008), 1482–1489.
53. 53 Williams, B., Lacy, P.S., CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol 54 (2009), 705–713.
54. 54 Laurent, S., Boutouyrie, P., Beta-blocker-induced heart rate reduction: too simplistic to explain the deleterious effects of beta-blockers. J Am Coll Cardiol 53 (2009), 2103–2104 author reply 2106–7.
55. 55 Ong, K.T., Perdu, J., De Backer, J., et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 376 (2010), 1476–1484.
56. 56 Steg, P.G., De Silva, R., Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence?. J Am Coll Cardiol 64 (2014), 253–255.
57. 57 Andersson, C., Shilane, D., Go, A.S., et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 64 (2014), 247–252.
58. 58 Bangalore, S., Steg, G., Deedwania, P., et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308 (2012), 1340–1349.
59. 59 Bangalore, S., Makani, H., Radford, M., et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 127 (2014), 939–953.
60. 60 Kjeldsen, S.E., Hedner, T., Syvertsen, J.O., et al., NORDIL Study Group. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hypertens 20 (2002), 1231–1237.
61. 61 Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol 66 (1990), 779–785.
62. 62 Bangalore, S., Messerli, F.H., Cohen, J.D., et al., INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 156 (2008), 241–247.
63. 63 DiFrancesco, D., Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 53 (2006), 399–406.
64. 64 Borer, J.S., Fox, K., Jaillon, P., et al., Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 (2003), 817–823.
65. 65 Swedberg, K., Komajda, M., Böhm, M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
66. 66 Rimoldi, S.F., Messerli, F.H., Cerny, D., et al. Selective heart rate reduction with ivabradine increases central blood pressure in stable coronary artery disease. Hypertension 67 (2016), 1205–1210.
67. 67 Sarnoff, S.J., Braunwald, E., Welch, G.H. Jr., et al. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol 192 (1958), 148–156.
68. 68 Laurent, P., Marenco, P., Castagna, O., et al. Differences in central systolic blood pressure and aortic stiffness between aerobically trained and sedentary individuals. J Am Soc Hypertens 5 (2011), 85–93.